Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Epinephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 0.84 |
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 0.84 |
| ▸ | ADRB3 known ✓ | P13945 | 4/20 | 0.84 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.84 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.84 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.84 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.84 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.84 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.84 |
| ▸ | MAPT | P10636 | 7/20 | 0.84 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.84 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.84 |
| ▸ | MEN1 | O00255 | 4/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.84 |
| ▸ | TSHR | P16473 | 4/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.84 |
| ▸ | MTOR | P42345 | 3/20 | 0.84 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epinephrine SCHEMBL9659298 | 1.00 | TDP1 (0.84) | TDP1KDM4EMAPTADRB2HSD17B10 | |
| Epinephrine SCHEMBL9659993 | 1.00 | TDP1 (0.84) | TDP1KDM4EMAPTADRB2HSD17B10 | |
| Racepinephrine SCHEMBL9659988 | 1.00 | TDP1 (0.84) | TDP1KDM4EMAPTADRB2HSD17B10 | |
| Racepinephrine SCHEMBL7921668 | 1.00 | TDP1 (0.84) | TDP1KDM4EMAPTADRB2HSD17B10 | |
| Racepinephrine SCHEMBL9659303 | 1.00 | TDP1 (0.84) | TDP1KDM4EMAPTADRB2HSD17B10 | |
| Racepinephrine SCHEMBL11631789 | 0.92 | KDM4E (1.00) | TDP1KDM4EMAPTADRB2HSD17B10 | |
| L-Adrenaline SCHEMBL11647 | 0.92 | KDM4E (1.00) | TDP1KDM4EMAPTADRB2HSD17B10 | |
| Racepinephrine SCHEMBL20493843 | 0.92 | KDM4E (1.00) | TDP1KDM4EMAPTADRB2HSD17B10 | |
| Epinephrine SCHEMBL2837188 | 0.92 | KDM4E (1.00) | TDP1KDM4EMAPTADRB2HSD17B10 | |
| Racepinephrine SCHEMBL3815 | 0.92 | KDM4E (1.00) | TDP1KDM4EMAPTADRB2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113453663-B | Stable injectable aqueous epinephrine solutions | 太阳医药工业有限公司 | 2024-07-05 | — | — | CN | claimed |
| US-11234925-B2 | Stable aqueous injectable solution of epinephrine | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2022-02-01 | — | — | US | claimed |
| US-20210353531-A1 | STABLE AQUEOUS INJECTABLE SOLUTION OF EPINEPHRINE | SUN PHARMACEUTICAL IND LTD (IN) | 2021-11-18 | — | — | US | claimed |
| CN-113453663-A | Stable injectable aqueous epinephrine solutions | 太阳医药工业有限公司 | 2021-09-28 | — | — | CN | claimed |
| WO-2020148609-A1 | A STABLE AQUEOUS INJECTABLE SOLUTION OF EPINEPHRINE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2020-07-23 | — | — | WO | claimed |
| US-20200214974-A1 | STABLE AQUEOUS INJECTABLE SOLUTION OF EPINEPHRINE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2020-07-09 | — | — | US | claimed |
| CN-104725628-B | A kind of single functionalization branched polyethylene glycol, preparation method and its bio-related substance containing degradable group | 厦门赛诺邦格生物科技股份有限公司 | 2018-04-17 | — | — | CN | claimed |
| WO-2017189528-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | Ecolab USA, Inc. (US) | 2017-11-02 | — | — | WO | claimed |
| US-20170306504-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | CHAMPIONX LLC | 2017-10-26 | — | — | US | claimed |
| EP-4349414-B1 | FORMULATIONS FOR TRANSDERMAL ADMINISTRATION | DYVE BIOSCIENCES INC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250262239-A1 | METHOD OF ADMINISTRATION AND TREATMENT | DYVE BIOSCIENCES, INC. | 2025-08-21 | — | — | US | disclosed |
| US-20250195664-A1 | TRANSDERMAL CARRIER | DYVE BIOSCIENCES, INC. | 2025-06-19 | — | — | US | disclosed |
| WO-2025125897-A1 | DEVICES FOR INJECTING MEDICAMENTS AND METHODS OF USE | MCDERMOTT LABORATORIES LIMITED (IE) | 2025-06-19 | — | — | WO | disclosed |
| US-12310983-B2 | Method of administration and treatment | DYVE BIOSCIENCES, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2017189528-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | Ecolab USA, Inc. (US) | 2017-11-02 | — | — | WO | disclosed |
| EP-3236903-A1 | METHODS AND FORMULATIONS FOR TRANSDERMAL ADMINISTRATION | Intellectual Property Associates, LLC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170306504-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | CHAMPIONX LLC | 2017-10-26 | — | — | US | disclosed |
| US-20160235851-A1 | Methods and formulations for transdermal administration | DYVE BIOSCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| WO-2016105499-A1 | METHODS AND FORMULATIONS FOR TRANSDERMAL ADMINISTRATION | INTELLECTUAL PROPERTY ASSOCIATES, LLC (US) | 2016-06-30 | — | — | WO | disclosed |
| US-6218575-B1 | ASYMMETRIC HYDROGENATION OF N-PROTECTED ADRENALONE USING DICHLOROBIS((CYCLOOCTA-1,5-DIENE) RHODIUM (I)) AND BIDENTATE PHOSPHINE LIGAND CATALYST SYSTEM; PRECIPITATION, DEBLOCKING | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353531-A1 | STABLE AQUEOUS INJECTABLE SOLUTION OF EPINEPHRINE | ALB, SELE, S100A11 | ADRB2 20/4885ADRB1 34/4885ADRB3 35/4885 |
| US-20250195664-A1 | TRANSDERMAL CARRIER | NACA, ETF1, SUCLG1 | ADRB2 2529/4885ADRB1 3261/4885ADRB3 2741/4885 |
| US-20200214974-A1 | STABLE AQUEOUS INJECTABLE SOLUTION OF EPINEPHRINE | ALB, SELE, S100A11 | ADRB2 20/4885ADRB1 34/4885ADRB3 35/4885 |
| US-11234925-B2 | Stable aqueous injectable solution of epinephrine | ALB, SELE, S100A11 | ADRB2 20/4885ADRB1 34/4885ADRB3 35/4885 |
| US-20160235851-A1 | Methods and formulations for transdermal administration | NACA, ETF1, KRT18 | ADRB2 2485/4885ADRB1 3431/4885ADRB3 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.